Recent Trends of <i>Helicobacter pylori</i> Eradication Therapy: Focusing on First Line Treatment

Kim, Ki Bang; Kim, Yong Sik

doi:2014.14.4.237

Korean J Helicobacter Up Gastrointest Res > Volume 14(4); 2014 > Article

Review

The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2014;14(4):237-241.
DOI: https://doi.org/10.7704/kjhugr.2014.14.4.237 Published online December 10, 2014.

Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment

Ki Bang Kim, Yong Sik Kim

Department of Internal Medicine, Eulji University College of Medicine, Daejeon, Korea. ykim0114@gmail.com

Helicobacter pylori 치료의 최신 지견:1차 제균 치료를 중심으로

김기방, 김용식

을지대학교 의과대학 내과학교실

Abstract

Helicobacter pylori infection causes peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid-tissue lymphoma. H. pylori eradication has played a major role in the prevention and treatment of these diseases. The guidelines for the diagnosis and treatment of H. pylori infection in Korea recommends standard triple therapy consisting of proton pump inhibitor, clarithromycin and amoxicillin as the first line eradication therapy and quadruple therapy including bismuth in case of clarithromycin-resistant H. pylori infection. However, the eradication rate of conventional first line therapy of H. pylori infection has been decreasing during the last decade. Recently the eradication rates of standard triple therapy in Korea is reported to be lower than 80% and sometimes even lower than 70% (intention-to-treat). Therefore, the need for new first line eradication regimens has been rising. Sequential therapy, concomitant therapy and tailored therapy have been introduced as new options for first line therapy. However, they have yet to be proven as standard therapy and need further studies.

Key Words: Helicobacter pylori; Eradication